Prognostic significance of angiogenesis in human pancreatic cancer
暂无分享,去创建一个
M. Adachi | C. Huang | Y. Nakajima | N. Ikeda | H. Kanehiro | M. Hisanaga | M. Sho | H. Nakano | H. Hashida | C Huang | Y Nakajima | H Kanehiro | M Hisanaga | M Sho | N Ikeda | H Nakano | M Miyake | M Adachi | T Taki | H Hashida | A Takabayashi | A. Takabayashi | T. Taki | M. Miyake | N. Ikeda | H. Hashida | C. Huang | M. Miyake | Cheng‐long Huang | Y. Nakajima | M. Adachi | Hiroshige Nakano | Y. Nakajima | Masayuki Miyake | Masashi Adachi | Hiroki Hashida | Masayuki Sho | A. Takabayashi | A. Takabayashi
[1] M. Kalser,et al. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer , 1987, Cancer.
[2] D. Gomez,et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. , 1996, Cancer research.
[3] A. Yoshimura,et al. Angiogenic factor , 1992, Nature.
[4] H. Friess,et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. , 1993, Cancer research.
[5] S. Akiba,et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. , 1996, Journal of the National Cancer Institute.
[6] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[7] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[8] T. Colby,et al. Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving? , 1995, Annals of surgery.
[9] L. Ellis,et al. The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.
[10] L. Ellis,et al. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[12] Vascular Endothelial Growth Factor In Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders , 1995 .
[13] J. Fiddes,et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.
[14] N. Olsen,et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.
[15] R. Kerbel,et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.
[16] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[17] M. Toi,et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] H. Friess,et al. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival , 1993 .
[19] B. Keyt,et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. , 1996, The Journal of clinical investigation.
[20] K. Inoue,et al. An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas , 1996, Cancer.
[21] K. Miyazono,et al. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. , 1992, Biochemical and biophysical research communications.
[22] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[23] Samuel Hellman,et al. Important advances in oncology , 1991 .
[24] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[25] J. Neoptolemos,et al. Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study , 1995, The British journal of surgery.
[26] H. Ohigashi,et al. [Chemotherapy for adenocarcinoma of the pancreas]. , 1997, Nihon Geka Gakkai zasshi.
[27] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[28] A. Cooperman,et al. Combined modality therapy for stage II and stage III pancreatic carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] D.,et al. Regression Models and Life-Tables , 2022 .
[30] V. Bautch,et al. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. , 1996, Cancer research.
[31] H. Friess,et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] E. Abel. Clinical applications of research on angiogenesis , 1996 .
[33] H. Dvorak,et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.
[34] D. Carter. TNM Classification of Malignant Tumors , 1998 .
[35] Schnall Sf,et al. Chemotherapy of adenocarcinoma of the pancreas. , 1996 .
[36] J. Winer,et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.
[37] K. Miyazono,et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor , 1989, Nature.
[38] W. McGuire,et al. Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.
[39] H. Hamada,et al. Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[40] L. Ellis,et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. , 1996, Journal of the National Cancer Institute.
[41] J. Folkman,et al. Tumoral vascularity as a prognostic factor in cancer. , 1996, Important advances in oncology.
[42] J. Isner,et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity , 1997, Nature Medicine.
[43] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[44] A. Choy,et al. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery , 1995, The Lancet.
[45] N. Lemoine,et al. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer , 1991, The Journal of pathology.
[46] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[47] S. Gansauge,et al. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. , 1996, Cancer research.